Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients

https://doi.org/10.1016/S0002-9149(00)80061-2Get rights and content

Abstract

In 482 patients sequentially referred for diagnosis and therapy of hyperlipidemia, our specific aim was to determine the prevalence of homocysteinemia, to assess whether it was independently associated with atherosclerotic vascular disease, and to determine how effectively high homocysteine could be treated with folic acid and pyridoxine. Of the 482 patients, 18 (3.7%) had high homocysteine (≥16.2 μmol/L, median = 19), 31 had high cystathionine (≥342 nmol/L) with normal homocysteine (median = 12), and 433 had normal cystathionine and homocysteine (median = 9). Of the 18 patients with high homocysteine, 13 (72%) had atherosclerotic vascular disease, much higher than the 44% (192 of 433 patients) with normal homocysteine (chisquare = 5.4, p = 0.02). In the 18 kindreds with a homocysteinemic proband, 14 (78%) had ≥1 firstdegree relatives with atherosclerotic vascular disease before age 65, compared with 50% (215 of 433) of the families where the proband had normal homocysteine (chi-square = 5.5, p = 0.02). In the 482 patients already at high risk for atherosclerotic vascular disease by virtue of hyperlipidemia, when assessed by logistic regression, homocysteine was an independent positive predictor of atherosclerotic vascular disease (p = 0.007); relative risk for atherosclerotic events was 2.8 times higher (p = 0.0004) in patients with top (≥11.4 μmol/L) than with bottom (<6.9 μmol/L) quintile homocysteine. After 15 weeks of folic acid (5 mg/day) and pyridoxine (100 mg/day) therapy in 10 patients with high homocysteine, median homocysteine normalized, decreasing from 18 to 11 μmol/L (p = 0.001). To best quantitate and ameliorate risk for atherosclerotic vascular disease, homocysteine should routinely be measured at least once in hyperlipidemic patients at high risk for atherosclerosis and, if high, should be treated.

References (30)

  • DudmanNPB et al.

    Disordered methionine-homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology

    Arterioscler Thromb

    (1993)
  • StamlerJS et al.

    Adverse vascular effects of homocysteine are modulated by endothelium derived relaxing factor and related oxides of nitrogen

    J Clin Invest

    (1976)
  • HarkerLA et al.

    Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis

    J Clin Invest

    (1976)
  • FrankenDG et al.

    Treatment of mild hyperhomocysteinemia in vascular disease patients

    Arterioscler Thromb

    (1994)
  • LevineD et al.

    Automated measurement of lipoprotein (a) by immunoturbidimetric analysis

    Int J Clin Lab Res

    (1992)
  • Cited by (157)

    • Serum homocysteine level and eye involvement in Egyptian patients with Behçet's disease

      2014, Egyptian Rheumatologist
      Citation Excerpt :

      Ocular involvement occurs in 50–70% of patients [3], and is characterized by periphlebitis, periarteritis, vascular occlusion, and thrombosis, which may lead to blindness despite intensive treatment [4]. The central feature of the histopathology of BD is an obliterative and necrotizing vasculitis that affects both the arteries and veins [5]. Homocysteine, derived from methionine, is a sulfur containing essential amino acid.

    • Plasma homocysteine is associated with ischemic findings without organic stenosis in patients with slow coronary flow

      2013, Journal of Cardiology
      Citation Excerpt :

      The main detrimental effects of Hcy are probably on vascular endothelium. The proposed mechanism by which endothelium is damaged by Hcy is impairment of the basal production of nitric-oxide (NO) in consequence of the emergence of some biochemically active products such as hydrogen peroxide (H2O2), superoxide anion (O2−) and hydroxyl radical (HO) [9,10,18–20]. In humans, reports demonstrated that elevated Hcy level was associated with impaired endothelium-dependent vasodilation and suggested that the bioavailability of NO was decreased in hyperhomocyst(e)inemic persons [18].

    • Cardiovascular effects of Danshen

      2007, International Journal of Cardiology
    View all citing articles on Scopus

    This study was supported in part by Jewish Hospital Medical Research Grants 738, 2728, and 733.

    View full text